ONL Therapeutics

FAS apoptosis inhibitors to protect photoreceptors and preserve patient vision from retinal diseases.  ONL is focused on preventing the death of key retinal cells, including photoreceptors—the root cause of vision loss and the leading cause of blindness.

(2014)

Location:
Ann Arbor

Management:
Johnn Freshley, CEO

UM Inventor(s):
David Zacks